[11C]OMAR
For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
[11C] JHU75528Loading study record…
Loading study record…
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-09-10
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand \[11C\] OMAR, in healthy individuals and individuals diagnosed with opioid use disorder. Research participants may complete screening, MRI, PET scan and follow up visits.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
[11C] JHU75528Eligibility
primary outcomes
Time frame: One time within 4 weeks of screening
To compare cortical CB1R availability in individuals diagnosed with opioid use disorder on chronic methadone maintenance vs. matched healthy controls.
secondary outcomes
Time frame: One time within 4 weeks of screening
To explore group differences in serum endocannabinoid levels in individuals diagnosed with opioid use disorder on chronic methadone maintenance vs. matched healthy controls.
Publications
No exact PMID-linked public article is currently readable locally.